Anti-PD1 Monoclonal Antibody Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Anti-PD-1 Monoclonal Antibody

Filter by location:

Columbus, Ohio1 trial

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Ohio State University Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.